Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02322866 · ClinicalTrials.gov registry record · Phase 3

Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

A Phase 3 study of Acne Vulgaris, sponsored by Almirall, S.A..

Completed
Registry status
Phase 3
Development phase
1,034
Enrollment target
20
Study locations

NCT02322866 is a Phase 3 study of Acne Vulgaris that has completed, run by Almirall, S.A.. The registered enrollment target is 1,034 participants, above the 260-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (298% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02322866, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Almirall, S.A..

COMPLETED
Registry status
Phase 3
Development phase
1,034 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris

Conditions Studied

Acne Vulgaris

Interventions

  • DRUG Placebo
  • DRUG Sarecycline

Study Locations (20)

Florida

  • Warner Chilcott Research Site (Site #237) - Aventura
  • Warner Chilcott Research Site (Site #226) - Clearwater
  • Warner Chilcott Research Site (Site #238) - Jupiter
  • Warner Chilcott Research Site (Site #255) - Lauderdale Lakes
  • Warner Chilcott Research Site (Site #249) - Miami
  • Warner Chilcott Research Site (Site #202) - Miami
  • Warner Chilcott Research Site (Site #211) - Miramar
  • Warner Chilcott Research Site (Site #247) - Ocala
  • Warner Chilcott Research Site (Site #241) - Orlando

California

  • Warner Chilcott Research Site (Site #245) - Carlsbad
  • Warner Chilcott Research Site (Site #234) - Encinitas
  • Warner Chilcott Research Site (Site #209) - Fremont
  • Warner Chilcott Research Site (Site #215) - Oceanside
  • Warner Chilcott Research Site (Site #204) - San Diego
  • Warner Chilcott Research Site (Site #254) - San Diego
  • Warner Chilcott Research Site (Site #257) - Santa Ana
  • Warner Chilcott Research Site (Site #243) - Santa Monica

Alabama

  • Warner Chilcott Research Site (Site #206) - Mobile

Arkansas

  • Warner Chilcott Research Site (Site #236) - Hot Springs

Colorado

  • Warner Chilcott Research Site (Site #222) - Denver

Trial Details

FieldValue
Enrollment Target 1,034 participants
Start Date 2014-12-03
Est. Completion 2017-01-12
Phase Phase 3

Sponsor

Almirall, S.A.

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02322866

The ClinicalTrials.gov registry entry for NCT02322866 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,034 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 260-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (298% higher). The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02322866 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT02322866 about?

NCT02322866 is a clinical study titled "Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne". To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris

What is the current status of trial NCT02322866?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,034 participants. The study started on 2014-12-03. Estimated completion is 2017-01-12.

What conditions does trial NCT02322866 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT02322866?

The interventions under investigation include: Placebo (DRUG), Sarecycline (DRUG).

Who is sponsoring clinical trial NCT02322866?

This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02322866 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acne Vulgaris

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.